Which hormones, metabolic markers, and bone density indicators to test — and when. Includes how each test is read against guideline and reference ranges, and how to interpret trends over time.
The menopausal transition makes single-point lab testing unreliable. Estradiol can swing from 20 to 300 pg/mL within weeks. FSH may be 40 one month and 20 the next. Progesterone depends entirely on whether ovulation occurred that cycle. This volatility doesn't mean testing is useless — it means you need to track trends over time rather than react to any single result.
The goal is to build a biomarker trajectory that shows you: where you are in the transition, how your metabolic health is shifting, whether interventions (exercise, nutrition, HRT) are working, and where emerging risks are developing before they become clinical problems.
These markers confirm menopausal staging and guide HRT decisions.
| Marker | How it's read | Notes |
|---|---|---|
| FSH | Varies by cycle phase and lab | Rises as ovarian function declines; single values fluctuate widely during perimenopause, so trends and symptoms say more than one result. |
| Estradiol (E2) | Varies by cycle phase and lab | Highly variable during perimenopause and low after menopause. Hormone therapy is judged on symptoms and risks, not on reaching a blood level. |
| Progesterone | Varies by cycle phase and lab | Only interpretable when matched to the phase of the cycle. |
| AMH | Age-specific; declines with age | Reflects remaining ovarian reserve. |
| Total testosterone | Varies by lab; ranges for women differ from men | Interpret with your clinician; testosterone ranges for men do not apply. |
| SHBG | Varies by sex and age | Binds testosterone and estradiol; oral estrogen raises it. |
| DHEA-S | Age- and sex-specific ranges | Declines with age; in a trial in older adults, supplements did not improve fitness, strength or insulin sensitivity. |
During perimenopause, draw FSH and estradiol on cycle day 2–5 (early follicular phase) for the most interpretable results. If cycles are too irregular to time, draw on any day but note where you are in the cycle. For progesterone, draw on day 21 (or 7 days after expected ovulation). Post-menopause: timing doesn't matter — draw anytime.
The menopausal transition accelerates metabolic changes that drive cardiovascular and diabetes risk. These markers are often more important for long-term health outcomes than the reproductive hormones themselves.
| Marker | How it's read | Notes |
|---|---|---|
| Fasting insulin | No agreed cut-off | Rises with insulin resistance; most useful tracked over time alongside glucose. |
| HbA1c | Normal under 5.7% · prediabetes 5.7–6.4% · diabetes 6.5%+ | Average blood sugar over about three months. |
| Fasting glucose | Normal under 100 mg/dL · prediabetes 100–125 · diabetes 126+ | A result in the diabetes range needs confirming with a repeat test. |
| HOMA-IR | No universal cut-off | Calculated from fasting insulin and glucose; thresholds vary with age, sex and population. |
| ApoB | No single cut-off | Counts atherogenic particles; read it with your overall cardiovascular risk. |
| LDL cholesterol | Desirable under 100 mg/dL · very high 190+ | The main target of cholesterol treatment. |
| HDL cholesterol | Low under 50 mg/dL for women · 60+ best | Low HDL is linked to higher cardiovascular risk. |
| Triglycerides | Normal under 150 mg/dL · borderline 150–199 · high 200+ | Very high levels (500+) can cause pancreatitis. |
| Lp(a) | Under 30 mg/dL (75 nmol/L) rules out risk · over 50 mg/dL (125 nmol/L) rules it in | Largely inherited; measure once in adulthood. |
| hsCRP | Low risk under 1 mg/L · average 1–3 · high over 3 | Infections raise CRP, so repeat a high result when you are well. |
Women commonly see LDL rise 10–15%, ApoB increase, triglycerides drift upward, and HDL decline during the menopausal transition — even with no dietary changes. This isn't "getting older" — it's estrogen loss directly affecting hepatic lipid metabolism. Track these markers every 6 months during the transition to catch accelerating risk early. Our Lab Results Interpreter can help you understand your numbers.
| Marker | How it's read | Notes |
|---|---|---|
| DEXA scan (T-score) | Read against the WHO categories on your report | The US Preventive Services Task Force recommends screening women 65 and older, and younger postmenopausal women at increased risk. |
| Vitamin D (25-OH) | Adequate 20–50 ng/mL · deficient under 12 · above 50 not advised (NIH) | The Endocrine Society's 2024 guideline suggests against routine testing without an established reason and found no clear evidence for any target level. |
| Calcium (serum) | Reference range varies by lab | Tightly regulated, so rarely abnormal; it does not reflect calcium intake or bone health. |
| TSH | Usual range about 0.4–4.8 mIU/L (labs vary) | Thyroid problems become more common with age and can mimic menopause symptoms. |
| Free T4 | Reference range varies by lab | Checked when TSH is abnormal. |
| Free T3 | Reference range varies by lab | Usually interpreted alongside TSH and free T4. |
| Ferritin | Iron deficiency below 15 ng/mL (below 70 with inflammation); above 150 may signal iron overload risk (WHO) | May rise after periods stop. Inflammation also raises ferritin. |
| Magnesium (serum) | Normal 1.7–2.2 mg/dL (labs vary slightly) | Only a small share of body magnesium is in the blood, so a normal level does not rule out low stores. |
| Vitamin B12 | Subnormal below 200–250 pg/mL | With symptoms and a level of 150–399 pg/mL, a methylmalonic acid test can confirm deficiency. |
Establish baselines. Get a comprehensive panel now — before things change dramatically. This gives you comparison points for the years ahead.
Increase frequency to every 6 months for hormones and metabolic markers. This is the period of most rapid change.
Annual testing is typically sufficient once hormones and metabolic markers stabilize.
Use our Blood Panel Builder to create a custom testing plan with Quest/LabCorp codes. Then use the Lab Results Interpreter to see how your results compare with guideline categories.
This is expected and not alarming. It confirms you're moving through the transition. Track the rate of change — rapid AMH decline suggests accelerated ovarian aging.
This is actionable. Even small increases in fasting insulin (from 3 to 6, or 6 to 10) signal emerging insulin resistance. Increase resistance training, reduce refined carbohydrates, and consider time-restricted eating. Retest in 3 months.
Expected during the transition but still requires attention. If ApoB rises above 90 mg/dL, discuss statin or other lipid-lowering therapy with your provider — especially if you have additional risk factors.
A decline of more than 3–5% between scans warrants intervention. Ensure adequate calcium (1,200 mg/day), vitamin D (40–60 ng/mL), and resistance + impact exercise. If T-score drops below -2.0, discuss bisphosphonates or HRT with your provider. See our Bone Density Optimization Protocol.
Common during menopause as visceral fat increases. Address through exercise, sleep optimization, omega-3 supplementation, and dietary anti-inflammatory patterns (Mediterranean diet). Persistent hs-CRP above 2.0 mg/L warrants further cardiovascular evaluation.
Use our Blood Panel Builder to select the right tests with Quest and LabCorp codes.
Build Your Panel →